CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...

Chris Gibson, Recursion’s head, cited the role small business grants played in helping Recursion grow its business.

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

That was the case for Recursion Pharmaceuticals, a now publicly traded company that applies artificial intelligence to drug discovery and development. With layoffs at the NIH underway and its ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

其中，Recursion Pharmaceuticals这颗星辰耀眼，股价一举上涨超过7%，引领了这一板块的强势反弹。作为一家专注于利用AI技术加速药物发现的生物制药公司，Recursion凭借其独特的技术平台和丰富的研发管线，备受资本市场青睐。公司致力于通过深度学习和生物数据分析来识别和开发潜在的治疗方案，近期关于其药物研发的积极进展无疑为投资者注入了信心。